Skip to content

Clinical efficacy and safety of photodynamic therapy on skin squamous cell carcinoma in situ and superficial basal cell carcinoma

Research in the management of diagnosis and therapy systems about many dermatosis and STD at Jiangsu province and transformation medical

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-13003625
Enrollment
Unknown
Registered
2013-08-29
Start date
2013-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin squamous cell carcinoma in situ & superficial basal cell carcinoma

Interventions

photodynamic therapy group:Each lesion soaked consecutively with 0.5ml ALA solution for 3 hours, which containing 118mg ammonia ALA hydrochloride) . Then uses helium-neon laser irradiate the lesion 20

Sponsors

Institute of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 75 years, male or female. Diagnosed with squamous cell carcinoma in situ skin or skin superficial basal cell carcinoma. Less than 3 Lesions. The diameter of each lesion not exceeding 4cm; Not received other local and systemic therapy in the two weeks prior to enrollment; Voluntarily participate in this study, and signed informed consent.

Exclusion criteria

Exclusion criteria: Where have any of the following conditions must be excluded subjects who entered the clinical studies: Not filled informed consent; Total number of lesions exceeds 3; Single lesion’s diameter larger than 4cm; Known to have skin photoallergy, porphyria; Known allergies to the study drug (porphyrin) and the similar chemical structure drugs; Lesion complicated with other obvious illness may affect the efficacy evaluation; Patients with physical scars or scarring tendency; Known to have severe immune dysfunction, or long-term use of corticosteroids and immunosuppressive agents; patients with severe heart, liver or kidney disease; With hereditary or acquired coagulation disorders; With serious neurological, psychiatric or endocrine disease.

Design outcomes

Primary

MeasureTime frame
Regression of lesion;Recurrence rate;Blood-routine;urine-routine;blood biochemical examination;

Secondary

MeasureTime frame
Skin pathology examination;

Countries

China

Contacts

Public ContactWeida Liu

Institute of Dermatology, Chinese Academy

liumyco@hotmail.com+86 025-85470580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026